[Discriminative ability, reclassification and net benefit: the predictive value of biomarkers].
More and more biomarkers are becoming available to predict the risk of disease. Several performance measures are used to express the predictive value of a biomarker. In this article we use as an example the Framingham risk score with and without the HDL cholesterol concentration as a risk factor for the prediction of the occurrence of cardiovascular disease. We consider 3 performance measures for diagnostic or prognostic quality: (a) the area under the Receiver Operating Characteristic (ROC) curve (AUC), a traditional measure to indicate discriminative ability; (b) the Net Reclassification Improvement (NRI), a popular measure based on the improvements in the high- and low-risk classification of patients by adding the HDL value as a risk factor; (c) Net Benefit, a measure based on decision sciences. Net benefit is a better measure for the value of a biomarker, since it takes more of the clinical context into account and is easier to interpret than the AUC and the NRI.
Duke Scholars
Published In
EISSN
Publication Date
Volume
Issue
Related Subject Headings
- General & Internal Medicine
Citation
Published In
EISSN
Publication Date
Volume
Issue
Related Subject Headings
- General & Internal Medicine